BRISTOL-MYERS SQUIBB COMPLETING COMPARISONS OF SERZONE AND SSRI INCIDENCE OF SEXUAL DYSFUNCTION, ANXIETY AND SLEEP DISORDERS; RELAPSE STUDIES ONGOING
Executive Summary
Bristol-Myers Squibb is completing two trials that compare the incidence of treatment- emergent sexual dysfunction among depressed patients taking either its recently-approved antidepressant Serzone (nefazodone) or one of the selective serotonin reuptake inhibitors.